Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
Marcia Frellick
Advertisement
Articles by Marcia Frellick
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP
2
ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
5 Hepatology Headlines You Missed in May 2026
5